News
ADXS
--
0.00%
--
72 Biggest Movers From Yesterday
Gainers
Benzinga · 09/14 08:50
21 Stocks Moving in Monday's Pre-Market Session
Gainers Itamar Medical Ltd. (NASDAQ: ITMR) rose 43% to $29.52 in pre-market trading. Zoll Medical said it has signed an agreement to acquire Itamar Medical for $31 per ADS in cash.
Benzinga · 09/13 11:07
Advaxis Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q3, Advaxis's (NASDAQ:ADXS) reported sales totaled $250.00 thousand. Despite a 34.65% increase in earnings, the company posted a loss of $4.13 million.
Benzinga · 09/10 15:54
BRIEF-Advaxis Reports Qtrly Loss Per Share Of $0.02
reuters.com · 09/10 15:00
Advaxis Q3 EPS $(0.02) Beats $(0.04) Estimate, Sales $250.00K
Advaxis (NASDAQ:ADXS) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 77.78 percent increase over losses of $(0.09) per share from the same
Benzinga · 09/10 12:32
-- Earnings Flash (ADXS) ADVAXIS Reports Q3 Revenue $250M
MT Newswires · 09/10 09:29
20 Stocks Moving in Friday's Pre-Market Session
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 59.5% to $8.77 in pre-market trading after the company announced the ApoGraft bone marrow transplantation of the first patient in the US.
Benzinga · 09/03 11:01
22 Stocks Moving in Thursday's Pre-Market Session
Gainers Good Works Acquisition Corp. (NASDAQ: GWAC) rose 29.8% to $13.01 in pre-market trading. Good Works Acquisition and Cipher Mining reported shareholder approval of business combination.
Benzinga · 08/26 11:12
Advaxis S-4 Filing Out Related To Proposed Merger Between Advaxis, Biosight
-SEC Filing
SEC Filing · 08/25 21:28
BRIEF-Advaxis Says Nasdaq Granted Extension To Regain Compliance With Minimum Bid Price Rule
reuters.com · 08/11 12:43
Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd.
Advaxis, Inc. (NASDAQ:ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products,
Benzinga · 08/11 12:12
Report 2021, Cervical Cancer Screening Market | Global Size, Share, Growth, Trends, Revenue Analysis, Competitive Landscape, Forecast 2028
The global cervical cancer screening market size is expected to gain momentum owing to the increasing prevalence of cancer during the forecast period. This information is published by Fortune Business Insights(TM) in an upcoming report, titled, "Cervical C...
GlobeNewswire · 07/22 06:58
Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy
Benzinga · 07/15 12:53
BRIEF-Advaxis Announces Initiation Of Phase 1 Clinical Trial Of ADXS-504 For Treatment Of Early Prostate Cancer
reuters.com · 07/15 12:41
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indicationMONMOUTH JUNCTION, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the devel...
GlobeNewswire · 07/15 12:00
Advaxis Starts Phase 1 Trial of Early Prostate Cancer Therapy
MT Newswires · 07/15 09:49
Advaxis To Present At The Non-Small Cell Lung Cancer Drug Development Summit Jul. 15
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and
Benzinga · 07/14 20:04
Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit
PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice ...
GlobeNewswire · 07/14 20:01
SeaSpine Lauded by Analysts After Spine Module Cleared by FDA
The Food and Drug Administration's cleared SeaSpine's 7D Percutaneous Spine Module for spinal surgery. The company's shares are higher.
TheStreet.com · 07/08 12:57
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers
Benzinga · 07/07 16:36
Webull provides a variety of real-time ADXS stock news. You can receive the latest news about Advaxis through multiple platforms. This information may help you make smarter investment decisions.
About ADXS
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of Listeria monocytogenes (Lm)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.